CDSCO Medical Device Import License in India: A Complete Guide for 2026

India’s medical device market continues to expand in 2026, driven by increased healthcare investment, rising demand for advanced technology, and stronger regulatory oversight. For foreign manufacturers and Indian importers, obtaining the correct approval remains the essential first step for lawful commercial supply. This guide provides a clear, practical overview of the process under current rules so that businesses can plan submissions accurately and avoid common delays.

Regulatory Framework for Imports

Medical devices in India are regulated under the Medical Devices Rules 2017, which operate within the broader framework of the Drugs and Cosmetics Act, 1940. The Central Licensing Authority, which is the Central Drugs Standard Control Organisation (CDSCO), holds exclusive responsibility for all import-related approvals. Devices are grouped according to risk-based classification into Class A (lowest risk), Class B, Class C, and Class D (highest risk). Class A non-sterile and non-measuring devices generally require only medical device registration, while Class A sterile or measuring devices, along with all Class B, C, and D devices, need a formal CDSCO import licence.

All applications are submitted electronically through the official SUGAM portal. Paper filings are no longer accepted.

Who Must Obtain the Licence and Who Can Apply?

Any person or organisation intending to bring medical devices into India for sale or distribution must hold a valid import licence. Overseas manufacturers cannot file applications directly. They are required to appoint an Authorized Indian Agent. This agent must already hold a valid wholesale licence or a registration certificate in Form MD-42 and serves as the legal point of contact with CDSCO. The agent prepares and submits the dossier, responds to queries, and remains accountable for ongoing regulatory compliance.

Core Application Forms

The standard application is filed in Form MD-14. After successful evaluation, CDSCO grants the licence in Form MD-15. Devices that have no predicate already approved or marketed in India may first require permission under Form MD-26 before the import pathway can proceed. Approvals already granted by recognised reference regulators (United States FDA, European Union, Japan, Canada, or Australia) strengthen the application and can reduce the need for additional local clinical data.

Key Documents for a Complete Dossier

A well-prepared technical file is critical. Essential documents normally include:

• Completed Form MD-14 together with proof of fee payment
• Power of Attorney from the overseas manufacturer, properly authenticated
• Undertaking signed by the Authorized Indian Agent
• Constitution details of the Indian agent
• Free Sale Certificate or equivalent marketing authorisation from the country of origin
• Valid ISO 13485 certification covering the manufacturing site
• Comprehensive Device Master File containing specifications, intended use, materials, risk analysis, and clinical evaluation data where required
• Plant Master File describing the manufacturing facility and quality systems
• Proposed labels, Instructions for Use, and packaging that meet Indian labelling requirements

For in-vitro diagnostic devices, additional performance evaluation reports from a registered laboratory are frequently requested. Incomplete or poorly organised files are the leading cause of queries and extended timelines.

Step-by-Step Process

1. Confirm the correct risk class of each device.
2. Appoint a qualified Authorized Indian Agent and execute the necessary legal documents.
3. Register the agent and overseas manufacturing site details on the SUGAM portal.
4. Compile and upload the full dossier with Form MD-14.
5. Pay the applicable fees (site fee plus per-device fee according to class).
6. Monitor the application and respond promptly to any CDSCO queries.
7. Receive Form MD-15 once the review is satisfactorily completed.

Official target timelines under the rules are approximately nine months from the date of a complete submission. Actual duration depends on dossier quality, device complexity, and the volume of queries raised.

Fees, Validity and Ongoing Obligations

Fees are prescribed in the Second Schedule of the Medical Devices Rules 2017 and are calculated on a per-site and per-device basis according to risk class. Exact amounts should always be verified on the portal at the time of filing. The licence is generally perpetual, subject to payment of a retention fee every five years and continued compliance. Any significant change in manufacturing site, constitution, or device specifications requires prior notification or a fresh application.

After the licence is granted, importers must maintain proper records, report adverse events, and ensure that labelling and distribution practices remain fully compliant. Customs authorities now follow standardised checklists aligned with CDSCO requirements, so the valid Form MD-15 and supporting documents must be readily available for clearance.

Why Choose MDR Consultants

Navigating medical device import regulations requires precise classification, high-quality technical documentation, and disciplined follow-up. Gaps in the Device Master File or delays in responding to queries frequently result in prolonged timelines. MDR Consultants specialises in end-to-end support for medical device companies seeking Indian market access. Our team assists with accurate risk classification, preparation of complete technical files, portal submissions, query management, and post-approval obligations, helping clients achieve faster and more predictable outcomes.

How MDR Consultants Supports Your Application

We begin with a detailed gap assessment of existing documentation against current CDSCO expectations. We then prepare or refine the Device Master File and Plant Master File, coordinate with the Authorized Indian Agent, handle online filing through the SUGAM portal, track application status, and provide clear strategic advice on device grouping or subsequent importer pathways. Whether you are introducing a first product or expanding an existing portfolio, structured regulatory support reduces risk and shortens time to market.

Conclusion

Securing a CDSCO import licence under the Medical Devices Rules 2017 is a structured but detail-intensive process. Success depends on correct risk-based classification, a complete and well-organised dossier, a properly appointed Authorized Indian Agent, and timely responses to regulatory queries. With India’s healthcare sector continuing to grow, accurate and efficient compliance opens significant commercial opportunities. Working with experienced specialists such as MDR Consultants converts a complex regulatory requirement into a clear, manageable pathway to lawful market entry and sustained regulatory compliance. Always verify the latest fee schedule and any procedural updates directly on the official CDSCO portal before submitting an application.

Last Updated : 15 Sep 2026